- Product Overview
Femular® (Ze 450) is a natural medicine that is clinically proven to relieve a wide range of menopausal symptoms.1-3 It is manufactured in Switzerland by Zeller AG, a herbal medicine company with over 130 years of experience in the research and production of natural medicines. Now Femular is also available as an EXTRA STRENGTH formulation, Femular FORTE that is suitable for those suffering from moderate to severe menopausal symptoms.
Femular and Femular Forte contain a specific extract of Actaea racemosa (Ze 450) that has been shown to assist in the symptomatic relief of a wide range of menopausal symptoms.
Menopausal symptoms can include:
- Hot flushes
- Sleep disturbances
- Nervousness, irritability
- Lack of concentration
- Joint pain
Once daily at first sign of menopausal symptoms.
For mild symptoms: Femular 1 tablet daily.
For moderate to severe symptoms: Femular Forte 1 tablet daily or 2 tablets of Femular.
Improvement in symptoms are expected after 1 month with a significant reduction in symptom severity after 3 months and continuing for a further 6 months.
Continue throughout the menopausal transition.
Always read the label. Use only as directed. If symptoms persist, or the condition recurs, it is important to speak with a healthcare professional.
Femular is an extract of Actaea racemosa that has been clinically proven, it is the exact product used in clinical trials.
Clinical trials have demonstrated that women using Femular have a significant reduction in menopausal symptoms. Some treatments used for menopausal symptoms may cause health concerns due to their oestrogenic action. Femular does not exert a direct oestrogenic effect.4 Femular is very well tolerated, with no report of serious adverse effects and no association with liver problems.5
References: 1. Schellenberg R et al 2012. Evid Based Complement Alternat Med. Epub December; ID 260301. 2. Saller R Cimicifuga. The efficacy is dose dependent (Wechseljahre: Pflanzliche 2. Alternativen auf dem Pruefstand) Menopause: Proven Herbal Alternatives 11.05.2005 PressClub Munich 3. Lopatka et al 2007. Journal for Menopause 2:1-7. 4. Garita-Hernandez et al 2006. Planta Med 72:1-7. 5. Periodic Safety Update Report for Ze 450, September 2011, Max Zeller Sohne AG
Some of this research was conducted using funding provided by Max Zeller Soehne AG, the manufacturer of this product
Maximum Quantity Allowed per customer: